Tag: CATALENT
Interim Results of Phase I Clinical Trial of TRPH-222 in R/R...
The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...
Triphase’s TRPH-222 enters Clinical Phase I trials
Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a...
Catalent Biologics and Vaccinex Ink Agreement to Jointly Develop Novel Antibody-Drug...
Catalent Pharma Solutions and Vaccinex confirmed their agreement earlier today to jointly develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag® conjugation platform and...
PEGS Boston 2017: Catalent Biologics Advances Antibody-Drug Conjugate Development
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that...
New Licensing Agreement Is Expected to Advance Catalent’s Proprietary SMARTag Technology...
This week, during the annual CPhI World Wide congress and exhibition being held in Barcelona, Spain, June 4 - 6, 2016, Catalent, the leading...
Roche and Catalent Start Research Collaboration on SMARTAG™ Technology
New Jersey based Catalent has agreed to a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using the company's proprietary SMARTag™...
Event Preview: CPhI Worldwide 2015
CPhI Worldwide 2015 returns to Madrid, Spain, for the 26th edition, bringing with it the booming pharmaceutical industry ready for a plethora of networking,...
Sanofi and Catalent Develop Next-Gen ADCs with SMARTag Technology
Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Sanofi-Aventis Recherche...
Toxicology Study Demonstrates Decreased Mortality and Better Tolerability of ADC Generated...
Results of an in vivo toxicology study, demonstrates that an Antibody Drug Conjugate or ADC generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC.
